Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Gibson

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
American Journal of Human Genetics|May 22, 2004
Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellitesSally John, Neil Shephard, Guoying Liu, et al.
British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 29, 2023
Recommendations from Diabetes UK's 2022 diabetes and physical activity workshopAnna Morris, Chris Bright, Matthew Cocks, et al.
Archives of Disease in Childhood|January 16, 2021
Indirect effects of the COVID-19 pandemic on paediatric healthcare use and severe disease: a retrospective national cohort studyThomas C Williams, Clare MacRae, Olivia V Swann, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs)Mark J Mulvihill, Julie L C Kan, Patricia Beck, et al.
Plos Medicine|December 7, 2016
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineGerald Goh, Ramona Schmid, Kelly Guiver, et al.
Pediatric Blood & Cancer|September 21, 2021
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcomaPascale Varlet, Eric Bouffet, Michela Casanova, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
British Journal of Cancer|December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)Albert Font, Begona Mellado, Miguel A Climent, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
American Journal of Human Genetics|May 22, 2004
Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellitesSally John, Neil Shephard, Guoying Liu, et al.
British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 29, 2023
Recommendations from Diabetes UK's 2022 diabetes and physical activity workshopAnna Morris, Chris Bright, Matthew Cocks, et al.
Archives of Disease in Childhood|January 16, 2021
Indirect effects of the COVID-19 pandemic on paediatric healthcare use and severe disease: a retrospective national cohort studyThomas C Williams, Clare MacRae, Olivia V Swann, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs)Mark J Mulvihill, Julie L C Kan, Patricia Beck, et al.
Plos Medicine|December 7, 2016
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineGerald Goh, Ramona Schmid, Kelly Guiver, et al.
Pediatric Blood & Cancer|September 21, 2021
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcomaPascale Varlet, Eric Bouffet, Michela Casanova, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
British Journal of Cancer|December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)Albert Font, Begona Mellado, Miguel A Climent, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Pageof 7